GLP1R and type 2 diabetes mellitus: Notably, it also revealed that patients who took metformin or sulfonylurea (SU) were less likely to have lifestyle dysregulation (p-value of 0.016, and 0.006, respectively), while patients who used glucagon-like peptide 1 receptor agonist (GLP1RA) and insulin injection as therapeutic agents of T2DM had more dysregulated lifestyle behaviors (p-value of 0.011 and 0.001, respectively).